Yuhan Corp. said it posted highest-ever annual sales in 2023 thanks to technology export revenue.

The company reported consolidated sales and operating profit of 1.8 trillion won ($1.3 billion) and 56.7 billion won in 2023, up 4.7 percent and 57.6 percent year-on-year. Net profit also jumped 57.4 percent to 142.5 billion won.

Key products such as the anti-inflammatory pain reliever Antiphlamine saw an 11.4 percent increase in sales, amounting to 33.2 billion won. The cholesterol-lowering drug Rosuvamibe (rosuvastatin) also reported a substantial growth of 53.7 percent, with sales reaching 84.9 billion won.

“The outstanding performance was possible thanks to the balanced growth across the parent, affiliated, and subsidiary companies,” a Yuhan official said. “The increase in licensing revenue played a significant role, with the subsidiary Add Pharma receiving 8.7 billion won in the past year.

In 2024, the company plans to focus on the global launch of Leclaza, a treatment for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC), the official added.

Janssen, Yuhan’s global partner for Leclaza, is currently undergoing the approval process in the U.S. and Europe for combination therapy with Janssen's dual antibody treatment, Rybrevant.